Investors seeking developed international equity exposure increasingly face a strategic fork: embrace broad, diversified coverage or tilt toward a single proven factor such as momentum. That is exactly the choice between FENI and IMTM. Both funds invest in developed markets outside the United States, yet they are built on fundamentally different engines. FENI blends active quantitative stock selection with the discipline of an index, while IMTM systematically harvests the momentum premium. Understanding how these structural differences shape sector exposure, cost, risk, and relative positioning is essential for any investor weighing the two. I also checked this using Tickeron’s AI Screener to see how the two compare on key metrics.
FENI is an actively managed, quantitatively driven fund that normally invests at least 80% of assets in common stocks within the MSCI EAFE Index, a capitalization-weighted benchmark of developed markets excluding the U.S. and Canada. Fidelity's computer-aided process overweights and underweights securities based on model output while keeping sector and industry weightings close to the benchmark, aiming to outperform with similar risk. The fund holds roughly 450 names, led by ASML Holding, Roche Holding, Nestlé, Novartis, Siemens AG, Tokyo Electron, Advantest, and Mitsubishi UFJ Financial Group. Sector exposure skews toward financials (about 26%), industrials (roughly 20–21%), technology (around 13%), and healthcare (near 11%), with Japan representing the largest single-country weight at roughly 23–24%. The net expense ratio is 0.28%.
IMTM is a passive, index-based fund that tracks the MSCI World ex USA Momentum Index, selecting developed-market large- and mid-capitalization stocks exhibiting relatively higher price momentum. The index rebalances on a semi-annual schedule, which can generate elevated turnover as momentum leadership rotates. The portfolio holds approximately 300 securities, with top positions including ASML Holding, Royal Bank of Canada, HSBC Holdings, Toronto-Dominion Bank, Shell, Novartis, Roche, and Banco Santander. Financials form the largest sector weight, followed by meaningful technology, energy, healthcare, and industrials exposure. The fund carries a 0.30% expense ratio and a three-year equity beta of roughly 0.72, reflecting its developed-market orientation with meaningful momentum concentration.
Both ETFs operate within the same broad macro canvas: developed international equities outside the U.S. In recent market cycles, that universe has been shaped by divergent central-bank policy, a firming global banking environment, and renewed capital flows into Europe and Japan as investors diversified away from concentrated U.S. tech leadership. Financials — a heavy weight in both funds — have benefited from a comparatively higher interest-rate backdrop that supports lending margins. Meanwhile, semiconductor-linked names such as ASML Holding and Japanese chip-testing and equipment firms have been propelled by sustained artificial-intelligence (AI) infrastructure spending. These forces tend to amplify momentum-style returns, favoring IMTM's factor tilt, while FENI's more balanced approach spreads exposure more evenly across sectors and countries.
Over recent weeks and months, the relative positioning of the two funds has diverged along their structural mandates. IMTM's momentum screen has kept it concentrated in leaders of the prevailing trends — global banks, energy majors, and AI-adjacent semiconductor and industrial names — allowing it to capture directional strength when those themes rally. FENI, by contrast, maintains tighter sector and country alignment to the MSCI EAFE benchmark, producing a smoother, more diversified return stream with less exposure to any single factor's reversal. As a result, IMTM has tended to display greater upside participation during momentum-driven rallies but also more sensitivity to sharp rotations, while FENI has offered steadier, benchmark-like behavior at a slightly lower cost. The key positioning distinction is concentration versus breadth: IMTM concentrates conviction in recent winners, whereas FENI spreads risk across the full developed-market opportunity set.
Based on observable factors, Tickeron's AI would likely favor IMTM in the current environment. The fund's momentum mandate aligns closely with trend-consistency signals that the AI tends to weight heavily, and its concentration in financials, energy, and AI-adjacent industrials positions it to capture prevailing leadership. IMTM's stronger relative trend profile supports a probabilistic edge over the near term. That said, FENI remains a more cost-efficient, diversified alternative for investors prioritizing controlled risk and broad developed-market coverage over factor concentration. The verdict reflects relative positioning rather than a universal recommendation for every investor.
In my own workflow, I frequently rely on Tickeron’s AI Screener when comparing ETFs like these. It lets me quickly filter across technical patterns, fundamentals, and performance metrics to see how holdings stack up against peers. The tool has helped me surface differences in momentum exposure and sector tilts that might otherwise take hours to analyze manually, giving a clearer picture of which approach fits a given portfolio.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IMTM declined for three days, in 209 of 269 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMTM as a result. In 62 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for IMTM turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 38 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
The Aroon Indicator for IMTM entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for IMTM's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMTM advanced for three days, in 255 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
IMTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows